CN103393730A - Oral ginkgo biloba extract liquid and preparation method thereof - Google Patents
Oral ginkgo biloba extract liquid and preparation method thereof Download PDFInfo
- Publication number
- CN103393730A CN103393730A CN2013103684569A CN201310368456A CN103393730A CN 103393730 A CN103393730 A CN 103393730A CN 2013103684569 A CN2013103684569 A CN 2013103684569A CN 201310368456 A CN201310368456 A CN 201310368456A CN 103393730 A CN103393730 A CN 103393730A
- Authority
- CN
- China
- Prior art keywords
- tween
- oral liquid
- preparation
- sodium
- ethanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 51
- 239000009429 Ginkgo biloba extract Substances 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title claims abstract description 29
- 229940068052 ginkgo biloba extract Drugs 0.000 title abstract 8
- 235000020686 ginkgo biloba extract Nutrition 0.000 title abstract 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 57
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 30
- 239000008213 purified water Substances 0.000 claims abstract description 25
- 239000000872 buffer Substances 0.000 claims abstract description 23
- 239000002904 solvent Substances 0.000 claims abstract description 15
- 241000218628 Ginkgo Species 0.000 claims description 40
- 235000011201 Ginkgo Nutrition 0.000 claims description 39
- 235000008100 Ginkgo biloba Nutrition 0.000 claims description 39
- 239000000284 extract Substances 0.000 claims description 35
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims description 28
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 26
- 229920000053 polysorbate 80 Polymers 0.000 claims description 26
- 239000000243 solution Substances 0.000 claims description 26
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 22
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 claims description 22
- -1 Tween-40 Polymers 0.000 claims description 18
- 239000004384 Neotame Substances 0.000 claims description 17
- 235000019412 neotame Nutrition 0.000 claims description 17
- HLIAVLHNDJUHFG-HOTGVXAUSA-N neotame Chemical compound CC(C)(C)CCN[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 HLIAVLHNDJUHFG-HOTGVXAUSA-N 0.000 claims description 17
- 108010070257 neotame Proteins 0.000 claims description 17
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 14
- 235000010265 sodium sulphite Nutrition 0.000 claims description 14
- XPFJYKARVSSRHE-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical group [Na+].[Na+].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XPFJYKARVSSRHE-UHFFFAOYSA-K 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 11
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 10
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 10
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 claims description 10
- 230000002421 anti-septic effect Effects 0.000 claims description 9
- 239000003963 antioxidant agent Substances 0.000 claims description 9
- 230000003078 antioxidant effect Effects 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 9
- 238000012856 packing Methods 0.000 claims description 9
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 8
- 239000004299 sodium benzoate Substances 0.000 claims description 8
- 235000010234 sodium benzoate Nutrition 0.000 claims description 8
- 230000001954 sterilising effect Effects 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 239000012982 microporous membrane Substances 0.000 claims description 7
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 7
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 7
- 229960003415 propylparaben Drugs 0.000 claims description 7
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 239000011259 mixed solution Substances 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 238000004659 sterilization and disinfection Methods 0.000 claims description 4
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 3
- BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical compound [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 claims description 3
- 108010011485 Aspartame Proteins 0.000 claims description 2
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 2
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 2
- 239000004376 Sucralose Substances 0.000 claims description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 2
- 239000000605 aspartame Substances 0.000 claims description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 2
- 235000010357 aspartame Nutrition 0.000 claims description 2
- 229960003438 aspartame Drugs 0.000 claims description 2
- CSVGEMRSDNSWRF-UHFFFAOYSA-L disodium;dihydrogen phosphate Chemical compound [Na+].[Na+].OP(O)([O-])=O.OP(O)([O-])=O CSVGEMRSDNSWRF-UHFFFAOYSA-L 0.000 claims description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 2
- 229960003885 sodium benzoate Drugs 0.000 claims description 2
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims description 2
- 235000010262 sodium metabisulphite Nutrition 0.000 claims description 2
- 229940013618 stevioside Drugs 0.000 claims description 2
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 2
- 235000019202 steviosides Nutrition 0.000 claims description 2
- 235000019408 sucralose Nutrition 0.000 claims description 2
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 2
- 239000012467 final product Substances 0.000 claims 1
- 238000002474 experimental method Methods 0.000 abstract description 5
- 235000019640 taste Nutrition 0.000 abstract description 4
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 3
- 230000001133 acceleration Effects 0.000 abstract description 2
- 230000033228 biological regulation Effects 0.000 abstract description 2
- 239000000796 flavoring agent Substances 0.000 abstract 2
- 235000013355 food flavoring agent Nutrition 0.000 abstract 2
- 239000003607 modifier Substances 0.000 abstract 2
- 239000003755 preservative agent Substances 0.000 abstract 2
- 230000002335 preservative effect Effects 0.000 abstract 2
- 239000006184 cosolvent Substances 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 abstract 1
- 238000009776 industrial production Methods 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 14
- 229930003935 flavonoid Natural products 0.000 description 14
- 150000002215 flavonoids Chemical class 0.000 description 14
- 235000017173 flavonoids Nutrition 0.000 description 14
- 229960004756 ethanol Drugs 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- MOLPUWBMSBJXER-YDGSQGCISA-N bilobalide Chemical compound O([C@H]1OC2=O)C(=O)[C@H](O)[C@@]11[C@@](C(C)(C)C)(O)C[C@H]3[C@@]21CC(=O)O3 MOLPUWBMSBJXER-YDGSQGCISA-N 0.000 description 12
- 235000007586 terpenes Nutrition 0.000 description 12
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 8
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 8
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 7
- 229930003944 flavone Natural products 0.000 description 7
- 235000011949 flavones Nutrition 0.000 description 7
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 239000013558 reference substance Substances 0.000 description 6
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 5
- GQODBWLKUWYOFX-UHFFFAOYSA-N Isorhamnetin Natural products C1=C(O)C(C)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 GQODBWLKUWYOFX-UHFFFAOYSA-N 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 5
- 235000008800 isorhamnetin Nutrition 0.000 description 5
- IZQSVPBOUDKVDZ-UHFFFAOYSA-N isorhamnetin Chemical compound C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 IZQSVPBOUDKVDZ-UHFFFAOYSA-N 0.000 description 5
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 5
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 5
- 235000005493 rutin Nutrition 0.000 description 5
- 229960004555 rutoside Drugs 0.000 description 5
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 4
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 230000001476 alcoholic effect Effects 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 235000008777 kaempferol Nutrition 0.000 description 4
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 4
- 235000005875 quercetin Nutrition 0.000 description 4
- 229960001285 quercetin Drugs 0.000 description 4
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 150000002212 flavone derivatives Chemical class 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 208000012902 Nervous system disease Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 229960000935 dehydrated alcohol Drugs 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000000916 dilatatory effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- SQFSKOYWJBQGKQ-UHFFFAOYSA-N kaempferide Chemical compound C1=CC(OC)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 SQFSKOYWJBQGKQ-UHFFFAOYSA-N 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 2
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 229960004249 sodium acetate Drugs 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 206010012305 Demyelination Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 229940123251 Platelet activating factor antagonist Drugs 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000008047 antioxidant nutrient Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000000782 cerebellar granule cell Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- 238000000105 evaporative light scattering detection Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- FPUXKXIZEIDQKW-MFJLLLFKSA-N ginkgolide A Natural products O=C1[C@H](C)[C@@]2(O)[C@@H](O1)C[C@]13[C@@H]4OC(=O)[C@]21O[C@@H]1OC(=O)[C@H](O)[C@]31[C@@H](C(C)(C)C)C4 FPUXKXIZEIDQKW-MFJLLLFKSA-N 0.000 description 1
- SQOJOAFXDQDRGF-WJHVHIKBSA-N ginkgolide B Natural products O=C1[C@@H](C)[C@@]2(O)[C@@H]([C@H](O)[C@]34[C@@H]5OC(=O)[C@]23O[C@H]2OC(=O)[C@H](O)[C@@]42[C@H](C(C)(C)C)C5)O1 SQOJOAFXDQDRGF-WJHVHIKBSA-N 0.000 description 1
- FPUXKXIZEIDQKW-VKMVSBOZSA-N ginkgolide-a Chemical compound O[C@H]([C@]12[C@H](C(C)(C)C)C[C@H]3OC4=O)C(=O)O[C@H]2O[C@]24[C@@]13C[C@@H]1OC(=O)[C@@H](C)[C@]21O FPUXKXIZEIDQKW-VKMVSBOZSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000003848 thrombocyte activating factor antagonist Substances 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses oral ginkgo biloba extract liquid which comprises the following components by mass proportioning: 80g ginkgo biloba extract, 2-10g flavoring agent, 8-15g antioxygen, 250-350g solubilizing agent, 0.5-10g preservative, 5-100g buffer liquid acidity modifier, 500-2000g 95% ethanol and 1000-9000g purified water. The oral ginkgo biloba extract liquid is formed in a manner that the ginkgo biloba extract serves as a raw material, an ethanol solution and a cosolvent are adopted for dissolution, and the preservative, the flavoring agent, the buffer liquid acidity modifier and the like are matched, so that the oral ginkgo biloba extract liquid is good in taste, and is particularly suitable for the aged and population with low sugar tolerance or diabetes. A high-temperature influence factor and strong light influence factor experiment, an acceleration stability experiment and a long-time stability experiment prove that the effective components in the oral ginkgo biloba extract liquid are in accordance with regulations in Chinese Pharmacopoeia 2010; a preparation is stable and can be stored for a long term; and the oral ginkgo biloba extract liquid is suitable for industrial production.
Description
Technical field
The present invention relates to pharmaceutical preparation, be specifically related to Chinese medicine extract, relate in particular to a kind of ginkgo leaf extract oral liquid and preparation method thereof.
Background technology
Folium Ginkgo is the leaf of Ginkgoaceae Ginkgo plant, and known Folium Ginkgo has important medical value and market value, and its main chemical compositions is flavonoid and terpene lactone compound, has developed many products that utilize Folium Ginkgo to make at present.
from the pharmacological action analysis, the flavone compound that Folium Ginkgo contains such as Quercetin, kaempferide and isorhamnetin etc., have blood vessel dilating and remove the spasm effect, the energy dilating coronary blood vessel, the increase coronary flow (Wang Benxiang. modern Chinese medicine pharmacology ［ M ］. Tianjin: Tianjin science tech publishing house, 1997:922-923), in addition, flavone compound also with reduce the blood ester, improve hemorheology, reduce LOP, improve relevant (the Ikeda K of SOD vigor, Negishi H, Yamori Y, et al.Antioxidant nutrients and hypoxia/ischemia brain injury in rodents ［ J ］ .Toxicology, 2003, 189 (122): 55261).Terpene lactone compound such as Ginkgolide A. B. C are strong platelet activating factor antagonist, (Wang Junmo. the pharmacological research of Folium Ginkgo. Chinese herbal medicine 1998; The 29(supplementary issue): 9) bilobalide has neuroprotective, similar nerve growth factor, the effect that promotes nerve growth is arranged, closely related with control nervous system disease and alzheimer disease, can be used for nervous system disease (the Chen C such as demyelination brain, spinal cord, Wei T, Gao Z, et aL.Diferent effects of the constitutents of Egb761on apoptosis in rat cerebellar granule cells induced by hydroxyl radicals ［ J ］ .Biochem Mol Biol lnt1999; 47 (3): 397).The pharmacological action of above-mentioned each effective ingredient, for the comprehensive drug of ginkgo leaf extract preparation is laid a good foundation.
Ginkgo leaf extract preparation is existing take solid preparations such as tablet, capsule, drop pill, dispersible tablet, granules as main.Consider that the dysphagia patien takes medicine, ginkgo leaf extract oral lyolysis this problem of having determined.Ginkgo leaf extract oral liquid, main effective ingredient is gingkgo flavonoids and terpene lactone, has the function of blood circulation promoting and blood stasis dispelling, collateral dredging, for the treatment of the diseases such as brain, peripheral vessels disturbance of blood circulation disease and organic dementia.But extract is not soluble, and in ginkgo leaf extract oral liquid, its main effective ingredient gingkgo flavonoids and terpene lactone are unstable in solution, have degraded in various degree, and taste is very bitter, and poor compliance, limited its clinical practice.Therefore, need to improve existing oral liquid formulations, improve its stability.
Summary of the invention
Technical problem to be solved by this invention is to overcome above-mentioned weak point, the research design good stability, and mouthfeel is good, is beneficial to clinical practice, and is suitable for ginkgo leaf extract oral liquid of suitability for industrialized production and preparation method thereof.
The invention provides a kind of ginkgo leaf extract oral liquid, by the one-tenth of following quality proportioning, be grouped into:
Folium Ginkgo extract 80, correctives 2～10, antioxidant 8～15, solubilizing agent 250～350, antiseptic 0.5～10, buffer acidity regulator 5～100,95% ethanol 500～2000, purified water 1000～9000.
Preferably, a kind of ginkgo leaf extract oral liquid of the present invention is grouped into by the one-tenth of following quality proportioning:
Folium Ginkgo extract 80, correctives 6, antioxidant 10, solubilizing agent 300, antiseptic 2, buffer acidity regulator 10,95% ethanol 1000, purified water 3592.
Described correctives is selected from one or more in neotame, sucralose, aspartame, stevioside or Fructus Citri Limoniae essence, is preferably the odor mask that mixes of neotame and Fructus Citri Limoniae essence combination.In mixing odor mask, the mass ratio of neotame and Fructus Citri Limoniae essence is 1:3～6, and the mass ratio of this mixing odor mask and Folium Ginkgo extract is 1:7～14.
Described antioxidant is selected from one or more in sodium pyrosulfite, sodium sulfite or thiourea, is preferably sodium sulfite.
Described solubilizing agent is selected from tween 80, Tween-40, tween 20 or Polyethylene Glycol, preferred tween 80 or Polyethylene Glycol.
Described antiseptic is one or more in sodium benzoate, methyl hydroxybenzoate, ethyl hydroxybenzoate or propylparaben, is preferably one or more in ethyl hydroxybenzoate, propylparaben or sodium benzoate
Described buffer is selected from citric acid-sodium citrate, acetic acid-sodium acetate or sodium hydrogen phosphate-sodium dihydrogen phosphate, is preferably citric acid-sodium citrate, and concentration is 0.1M, pH of buffer=6.0.
Another object of the present invention has been to provide the preparation method of above-mentioned a kind of ginkgo leaf extract oral liquid.
The method is by 95% ethanol, tween 80, PEG400 mix homogeneously, adds respectively Folium Ginkgo extract, antiseptic to be stirred to dissolve; Add correctives, antioxidant, appropriate purified water is stirred to dissolve, and with buffer, regulates pH to 4.5～5.5 again, finally with the purified water standardize solution, crosses 0.25 μ m filtering with microporous membrane degerming packing, or sterilizing after packing, and 5mL/ props up or 10mL/ props up.
In preparation, tween 80 and PEG400 (mass ratio of the two is 1:0.5～2) are solvent with the mixed solution that 95% ethanol forms, and the mass ratio of tween 80 and PEG400 mixed liquor and 95% ethanol is 1:1.5～4, is preferably 1:1.6～3.4.
The mass ratio of Folium Ginkgo extract and solvent is 1:2～40, is preferably 1:15～20.
Described degerming method is filtration sterilization or moist heat sterilization.
In development of the present invention, by the inventor's innovation, solved the problem that prior art exists, reached good effect.
(1) because the effective ingredient of Folium Ginkgo extract is not soluble, test after deliberation, the inventor is surprised to find with tween 80, PEG400, alcoholic solution and mixes by a certain percentage and make solvent, can obtain the Folium Ginkgo extract concentrated solution of clear.
(2) Folium Ginkgo extract ingredient complexity, comprise the multiclass composition, in alone alcoholic solution or alcoholic solution, add separately tween 80 or PEG400 or other solubilizing agents all can not dissolve all the components fully, through the present invention, repeatedly study, tween 80 and PEG400 are share and control to the mixed solution of tween 80 and the preparation of PEG400 mass ratio, the effective ingredient in the Folium Ginkgo extract of effective clinical using dosage is fully dissolved.
(3) in Folium Ginkgo extract, flavone compound itself has obvious bitter taste, and general user is difficult to accept, and must correct with the correctives that is suitable for, and traditional correctives is take sucrose or Mel as main.Owing to considering that taking in object of this oral liquid comprises old people and group, carbohydrate tolerance is low or diabetic population, so the present invention finds and selects not contain the odor mask of carbohydrate content.Because Folium Ginkgo extract composition kind is various, and taste and uncomfortable mouthfeel be derived from heterogeneity, finds after deliberation, and single odor mask is difficult to realize effective taste masking.Through research discovery repeatedly, neotame and Fructus Citri Limoniae essence with proper proportion are made correctives, and the combination odor mask that forms when the two mass ratio is 1:3～6, this combination odor mask and Folium Ginkgo extract mass ratio are 1:7～14 o'clock, can effectively cover the bitter taste in Folium Ginkgo extract, too much very few neither suitable.Ginkgo leaf extract oral liquid good mouthfeel of the present invention, suitable especially elderly population, carbohydrate tolerance is low or diabetic population.
(4) in ginkgo leaf extract oral liquid research process, the inventor finds, when pH value>5.5, bilobalide is easily degraded, and pH value<4.5 o'clock, flavone compound is easily degraded, therefore design and selected multiple buffer salt, through research discovery repeatedly, with buffer, regulate pH value between 4.5～5.5, can guarantee effectively that the oral liquid acid-base value is stable.
Ginkgo leaf extract oral liquid prepared by the present invention; by temperatures involved factor, high light influence factor, acceleration experiment, long-time stability experiment; detect every effective ingredient and meet the pharmacopeia regulation; the effective ingredient of Folium Ginkgo extract has obtained good protection; preparation stabilization; but long preservation, be suitable for producing.
The specific embodiment
Following examples are used for the present invention is described, but are not used for limiting the scope of the invention.
Folium Ginkgo extract for embodiment is bought from commercially available prod, and prescription meets the every quality standard of 2010 editions Chinese Pharmacopoeias " Folium Ginkgo extract ".
Embodiment 1
| Folium Ginkgo extract | 80g |
| 95% ethanol | 800g |
| Tween 80 | 150g |
| PEG400 | 150g |
| Ethyl hydroxybenzoate | 1g |
| Propylparaben | 1g |
| Sodium sulfite | 10g |
| Neotame | 1g |
| Fructus Citri Limoniae essence | 5g |
| The citric acid-sodium citrate buffer | 10g |
| Purified water | 8792g |
Preparation: 95% ethanol, tween 80, PEG400 mix homogeneously, add respectively Folium Ginkgo extract, ethyl hydroxybenzoate and propyl ester are stirred to dissolve; Add again neotame, Fructus Citri Limoniae essence, sodium sulfite, appropriate purified water to be stirred to dissolve, with the citric acid-sodium citrate buffer, regulate pH=5.0, finally with purified water, be settled to 10L, cross 0.25 μ m filtering with microporous membrane degerming packing 10mL/ and prop up, totally 1000 ginkgo leaf extract oral liquid.
The product ginkgo leaf extract oral liquid testing result of preparation is as follows:
Clarity detects with YB-2 type clarity detecting apparatus.
Total flavonoids detects: according to high performance liquid chromatography (appendix VI D of Chinese Pharmacopoeia version in 2010), measure.
Chromatographic condition and system suitability: with octadecylsilane chemically bonded silica, be filler; Take methanol-0.4% phosphoric acid solution (50:50) as mobile phase; The detection wavelength is 360nm.Number of theoretical plate calculates and should be not less than 2500 by the Quercetin peak, and the separating degree at kaempferol peak and isorhamnetin peak should be greater than 1.5.
The preparation of reference substance solution: precision takes the Quercetin more than 12 hours, kaempferol, isorhamnetin reference substance through the phosphorus pentoxide drying under reduced pressure respectively, adds methanol and makes the solution that every 1ml contains 30 μ g, 30 μ g, 20 μ g, product solution in contrast.The preparation of need testing solution: precision measures this product 4mL, adds methanol 10ml, 25% hydrochloric acid solution 5ml, shakes up, and puts in water-bath reflux 30 minutes, take out, be cooled to rapidly room temperature, be transferred in the 50ml measuring bottle, add methanol and be diluted to scale, shake up, filter, get subsequent filtrate, obtain.Precision is drawn reference substance solution and each 10 μ l of need testing solution respectively, and the injection liquid chromatography, measure, and calculates respectively the content of Quercetin, kaempferol and isorhamnetin, by following formula, is converted into the content of total flavonoids.
Total flavonoids content=(quercetin content+kaempferol content+isorhamnetin content) * 2.51
Every of this product contains total flavonoids content and is no less than 19.2mg,
Terpene lactone contents detects: according to high performance liquid chromatography (appendix VID of Chinese Pharmacopoeia version in 2010), measure.
Chromatographic condition and system suitability: with octadecylsilane chemically bonded silica, be filler; Take normal propyl alcohol-oxolane-water (1:15:84) as mobile phase, with evaporative light scattering detector, detect.Number of theoretical plate calculates and should be not less than 2500 by the bilobalide peak.
The preparation of reference substance solution: accurate ester A processed, ginkalide B and the ginkalide C reference substance of taking in the phosphorus pentoxide drying under reduced pressure bilobalide of 12 hours, Semen Ginkgo is appropriate respectively, add methanol and make the mixed solution that every 1ml contains 2mg, 1mg, 1mg, 1mg, obtain.The preparation of need testing solution: precision measures this product 16mL, add 2 of 2% hydrochloric acid solutions, with the ethyl acetate jolting, extract 4 times (30ml, 15ml, 15ml, 15ml), merge extractive liquid,, with 5% sodium acetate solution 20m washing, divide and get sodium acetate liquid, with ethyl acetate 10ml, wash, merge ethyl acetate extraction liquid and washing liquid, wash with water 2 times, each 20ml, merge water lotion, with ethyl acetate 10ml washing, merge ethyl acetate liquid, the recovery of acetic acid ethyl ester is to doing, residue makes to dissolve and is transferred in the 5ml measuring bottle with acetone, add acetone to scale, shake up, obtain.Precision is drawn reference substance solution 5 μ l, 10 μ l and need testing solution 20 μ l respectively, and the injection liquid chromatography is measured, and with external standard two-point method logarithmic equation, calculates respectively the content of ester A processed, ginkalide B and ginkalide C in bilobalide, Semen Ginkgo, obtains.
Every of this product contains terpene lactone with bilobalide (C
15H1
8O
8), ginkalide A (C
20H
24O
9), ginkalide B (C
20H
24O
10) and ginkalide C (C
20H
24O
11) the total amount meter, must not be less than 4.8mg.
Determination of total flavonoids: get the control substance of Rutin 20.0mg of 120 ℃ of drying under reduced pressure to constant weight, to the 100mL measuring bottle, add 70% alcoholic solution dilution standardize solution, shake up, obtain (every 1mL contains anhydrous rutin 0.2mg), precision measures control substance of Rutin 0.2mL, 0.4mL, 0.6mL, 0.8mL, 1.0mL, 1.2mL, is placed in respectively the 10mL measuring bottle, respectively adds water to 3mL, add acetic acid-sodium-acetate buffer (pH4.5) 2mL, mix, add 70% ethanol to scale, shake up.Take corresponding solution as blank.According to ultraviolet visible spectrophotometry (two appendix IV A of Chinese Pharmacopoeia version in 2010), at the wavelength place of 273nm, measure respectively absorbance, take absorbance as vertical coordinate, concentration is abscissa, the drawing standard curve.
Need testing solution preparation, precision measures this product 2mL, puts in the 50mL measuring bottle, adds purified water dilution standardize solution, shakes up, and precision measures 1mL, puts in the 10mL measuring bottle, under sighting target directrix curve preparation, " respectively adds water to 3mL " and rise to measure absorbance in accordance with the law.From standard curve, read test sample the general flavone content that is equivalent to rutin, calculate the general flavone content that is equivalent to rutin in every oral liquid.
PH value detects with DELTA320 type pH meter.
In every oral liquid, total flavonoids content and terpene lactone contents meet 2010 editions Chinese Pharmacopoeia requirements, and study on the stability is qualified.
The ginkgo leaf extract oral liquid study on the stability result that makes:
Embodiment 2
| Folium Ginkgo extract | 80g |
| 95% ethanol | 900g |
| Tween 80 | 150g |
| PEG400 | 150g |
| Sodium benzoate | 10g |
| Sodium sulfite | 10g |
| Neotame | 1g |
| Fructus Citri Limoniae essence | 5g |
| The citric acid-sodium citrate buffer | 10g |
| Purified water | 8684g |
Preparation: 95% ethanol, tween 80, PEG400 mix homogeneously, add Folium Ginkgo extract, be stirred to dissolve; Add sodium benzoate, neotame, Fructus Citri Limoniae essence, sodium sulfite, appropriate purified water, be stirred to dissolve, with the citric acid-sodium citrate buffer, regulate pH=5.0, finally with purified water, be settled to 10L, cross after 0.25 μ m filtering with microporous membrane packing sterilizing (100 ℃, 10 minutes), 10mL/ props up, totally 1000 ginkgo leaf extract oral liquid.
Detection method is with embodiment 1, and in every oral liquid, total flavonoids content is no less than 19.2mg, and terpene lactone contents is no less than 4.8mg, meet 2010 editions Chinese Pharmacopoeia requirements, and study on the stability is qualified.
The ginkgo leaf extract oral liquid study on the stability result that makes:
Embodiment 3
| Folium Ginkgo extract | 80g |
| Dehydrated alcohol | 1000g |
| Tween 80 | 150g |
| PEG400 | 150g |
| Ethyl hydroxybenzoate | 1g |
| Propylparaben | 1g |
| Sodium sulfite | 10g |
| Neotame | 1g |
| Fructus Citri Limoniae essence | 5g |
| The citric acid-sodium citrate buffer | 10g |
| Purified water | 3592g |
Preparation: dehydrated alcohol, tween 80, PEG400 mix homogeneously, add respectively Folium Ginkgo extract, ethyl hydroxybenzoate and propyl ester are stirred to dissolve; Add again neotame, Fructus Citri Limoniae essence, sodium sulfite, appropriate purified water to be stirred to dissolve, with the citric acid-sodium citrate buffer, regulate pH=5.0, finally with purified water, be settled to 5L, cross 0.25 μ m filtering with microporous membrane degerming packing, 5mL/ props up, totally 1000 ginkgo leaf extract oral liquid.
Detection method is with embodiment 1, but total flavonoids content, terpene lactone contents, general flavone content detect the oral liquid sampling to reduce by half respectively, be respectively total flavonoids content in 2mL, 8mL, 1mL, every oral liquid and be no less than 19.2mg, terpene lactone contents is no less than 4.8mg, and study on the stability is qualified.The ginkgo leaf extract oral liquid study on the stability result that makes:
Embodiment 4
| Folium Ginkgo extract | 80g |
| 95% ethanol | 600g |
| Tween 80 | 140g |
| PEG400 | 200g |
| Sodium benzoate | 8g |
| Sodium sulfite | 10g |
| Neotame | 1g |
| Fructus Citri Limoniae essence | 5g |
| The citric acid-sodium citrate buffer | 10g |
| Purified water | 8946g |
Preparation: 95% ethanol, tween 80, PEG400 mix homogeneously, add Folium Ginkgo extract, be stirred to dissolve; Add sodium benzoate, neotame, Fructus Citri Limoniae essence, sodium sulfite, appropriate purified water, be stirred to dissolve, with the citric acid-sodium citrate buffer, regulate pH=5.0, finally with purified water, be settled to 10L, cross after 0.25 μ m filtering with microporous membrane packing sterilizing (100 ℃, 10 minutes), 10mL/ props up, totally 1000 ginkgo leaf extract oral liquid.
Detection method is with embodiment 1, and in every oral liquid, total flavonoids content is no less than 19.2mg, and terpene lactone contents is no less than 4.8mg, meet 2010 editions Chinese Pharmacopoeia requirements, and study on the stability is qualified.
The ginkgo leaf extract oral liquid study on the stability result that makes:
Embodiment 5
| Folium Ginkgo extract | 80g |
| 95% ethanol | 700g |
| Tween 80 | 200g |
| PEG400 | 150g |
| Ethyl hydroxybenzoate | 1g |
| Propylparaben | 1g |
| Sodium sulfite | 8g |
| Neotame | 1g |
| Fructus Citri Limoniae essence | 5g |
| The citric acid-sodium citrate buffer | 15g |
| Purified water | 8839g |
Preparation: 95% ethanol, tween 80, PEG400 mix homogeneously, add respectively Folium Ginkgo extract, ethyl hydroxybenzoate and propyl ester are stirred to dissolve; Add again neotame, Fructus Citri Limoniae essence, sodium sulfite, appropriate purified water to be stirred to dissolve, with the citric acid-sodium citrate buffer, regulate pH=5.5, finally with purified water, be settled to 10L, cross 0.25 μ m filtering with microporous membrane degerming packing 10mL/ and prop up, totally 1000 ginkgo leaf extract oral liquid.
Detection method is with embodiment 1, and in every oral liquid, total flavonoids content is no less than 19.2mg, and terpene lactone contents is no less than 4.8mg, meet 2010 editions Chinese Pharmacopoeia requirements, and study on the stability is qualified.
The ginkgo leaf extract oral liquid study on the stability result that makes:
Claims (10)
1. a ginkgo leaf extract oral liquid, is characterized in that, described oral liquid is grouped into by the one-tenth of following quality proportioning:
Folium Ginkgo extract 80, correctives 2～10, antioxidant 8～15, solubilizing agent 250～350, antiseptic 0.5～10, buffer acidity regulator 5～100,95% ethanol 500～2000, purified water 1000～9000.
2. a ginkgo leaf extract oral liquid, is characterized in that, described oral liquid is grouped into by the one-tenth of following quality proportioning:
Folium Ginkgo extract 80, correctives 6, antioxidant 10, solubilizing agent 300, antiseptic 2, buffer acidity regulator 10,95% ethanol 1000, purified water 3592.
3. described a kind of ginkgo leaf extract oral liquid according to claim 1 and 2, is characterized in that, described correctives is selected from one or more in neotame, sucralose, aspartame, stevioside or Fructus Citri Limoniae essence; Described antioxidant is selected from one or more in sodium pyrosulfite, sodium sulfite or thiourea; Described solubilizing agent is selected from tween 80, Tween-40, tween 20 or Polyethylene Glycol; Described antiseptic is selected from one or more in sodium benzoate, methyl hydroxybenzoate, ethyl hydroxybenzoate or propylparaben; Described buffer is selected from citric acid-sodium citrate, acetic acid-sodium acetate or sodium hydrogen phosphate-sodium dihydrogen phosphate.
4. a kind of ginkgo leaf extract oral liquid according to claim 3, it is characterized in that, described correctives is neotame and the odor mask that mixes of Fructus Citri Limoniae essence combination, described being somebody's turn to do mixed in odor mask, the mass ratio of neotame and Fructus Citri Limoniae essence is 1:3～6, and the mass ratio of this mixing odor mask and Folium Ginkgo extract is 1:7～14; Described antioxidant is sodium sulfite; Described solubilizing agent is tween 80 or Polyethylene Glycol; Described antiseptic is one or more in ethyl hydroxybenzoate, propylparaben or sodium benzoate; Described buffer is citric acid-sodium citrate.
5. prepare a kind of method of ginkgo leaf extract oral liquid as claimed in claim 1 or 2, it is characterized in that,
The method is by 95% ethanol, tween 80, PEG400 mix homogeneously, adds respectively Folium Ginkgo extract and antiseptic, is stirred to dissolve; Add correctives, antioxidant, appropriate purified water is stirred to dissolve again, and with buffer, regulates pH to 4.5～5.5, finally with the purified water standardize solution, crosses 0.25 μ m filtering with microporous membrane degerming packing, or sterilizing and get final product after packing.
6. preparation method according to claim 5, is characterized in that, the mixed solution that described tween 80 and PEG400 and 95% ethanol form is solvent; The mass ratio of described tween 80 and PEG400 mixed liquor and 95% ethanol is 1:1.5～4, is preferably 1:1.6～3.4; The mass ratio of tween 80 and PEG400 is 1:0.5～2.
7. preparation method according to claim 6, is characterized in that, the mass ratio of tween 80 and PEG400 mixed liquor and 95% ethanol is 1:1.6～3.4.
8. preparation method according to claim 5, is characterized in that, the mass ratio of Folium Ginkgo extract and solvent is 1:2～40.
9. preparation method according to claim 8, is characterized in that, the mass ratio of Folium Ginkgo extract and solvent is 1:15～20.
10. preparation method according to claim 5, is characterized in that, described degerming method is filtration sterilization or moist heat sterilization.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013103684569A CN103393730A (en) | 2013-08-21 | 2013-08-21 | Oral ginkgo biloba extract liquid and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013103684569A CN103393730A (en) | 2013-08-21 | 2013-08-21 | Oral ginkgo biloba extract liquid and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103393730A true CN103393730A (en) | 2013-11-20 |
Family
ID=49557585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2013103684569A Pending CN103393730A (en) | 2013-08-21 | 2013-08-21 | Oral ginkgo biloba extract liquid and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103393730A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108210528A (en) * | 2018-02-12 | 2018-06-29 | 浙江圣博康药业有限公司 | A kind of preparation method of ginkgo-leaf oral liquor |
| CN108853464A (en) * | 2018-09-26 | 2018-11-23 | 浙江圣博康药业有限公司 | A kind of preparation method of ginkgo-leaf oral liquor |
| CN109223838A (en) * | 2018-11-07 | 2019-01-18 | 青岛旺尚生物技术有限公司 | A kind of preparation method and applications of ginkgo leaf extract oral liquid |
-
2013
- 2013-08-21 CN CN2013103684569A patent/CN103393730A/en active Pending
Non-Patent Citations (1)
| Title |
|---|
| 营佳等: "银杏叶口服液的研制", 《中国生化药物杂志》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108210528A (en) * | 2018-02-12 | 2018-06-29 | 浙江圣博康药业有限公司 | A kind of preparation method of ginkgo-leaf oral liquor |
| CN108853464A (en) * | 2018-09-26 | 2018-11-23 | 浙江圣博康药业有限公司 | A kind of preparation method of ginkgo-leaf oral liquor |
| CN109223838A (en) * | 2018-11-07 | 2019-01-18 | 青岛旺尚生物技术有限公司 | A kind of preparation method and applications of ginkgo leaf extract oral liquid |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101357146B (en) | Preparation method of chimonanthus nitens valid target, production method and use of formulation thereof | |
| CN100457139C (en) | Method for preparing a Shuanhuanglian injection and the component detecting method | |
| CN101856473B (en) | Children's Qixing tea oral liquid and its preparing method | |
| AU2007218733A1 (en) | Pharmaceutical composition comprising oseltamivir phosphate | |
| CN102846600B (en) | Oxiracetam drug activity composition and preparation method thereof | |
| CN104447904B (en) | Stable gastrodine crystal that a kind of oral administration biaavailability is high and preparation method thereof, preparation and application | |
| CN103393730A (en) | Oral ginkgo biloba extract liquid and preparation method thereof | |
| CN102058814B (en) | General flavone extractive of four medicaments including grassleaf sweetflag rhizome and preparation method thereof | |
| CN103191116A (en) | Dextromethorphan hydrobromide and guaiacol glycerin ether oral liquid and preparation method thereof | |
| CN105287610A (en) | Application of forsythiaside I and preparation method thereof | |
| CN101766664A (en) | Extraction method of total saponin of Radix Ilicis Asprellae and quality detection method thereof | |
| CN104398950A (en) | Four-flavored calamus anticancer extract, as well as preparation method and application of four-flavored calamus anticancer extract | |
| CN109010409A (en) | The extraction and purification process and detection method of content of flavonoid compound in a kind of people face fruit leaf | |
| CN103923138B (en) | A kind of preparation method of Nicotifiorin and application thereof | |
| CN101019837B (en) | Ginnone ester dispersing table and its preparation method | |
| US8603548B2 (en) | Anti-avian influenza virus agent, and product containing anti-avian influenza virus agent | |
| CN106420851B (en) | A kind of Shu Xuening injection and preparation method thereof | |
| CN103833650A (en) | Ligustrazine phosphate compound and medicine composition containing the ligustrazine compound and gingko leaf effective ingredient | |
| CN114588187B (en) | Traditional Chinese medicine total flavone extract for treating cataract, and composition, preparation method and medical application thereof | |
| Piri et al. | Phytoequivalency of Ginkgo biloba products: Pharmacopoeial method | |
| CN100366629C (en) | Preparation process of high-purity scutellarin bulk drug | |
| CN102423326B (en) | The use of the total flavonoids of bell flower and primrose | |
| CN103193738B (en) | Dehydroandrographolide succinate crystal and use thereof | |
| Kothawade et al. | Proximate Phytochemical analysis of Corallocarpus epigaeus (Arn.) Cl rhizomes and Vernonia anthelmintica willd seeds | |
| CN106279317B (en) | A method of preparing Quercetin -3-o- glucoside from ginkgo biloba p.e |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20131120 |